Remote Buying of Acadia Pharmaceuticals Inc through IEX is under development on ETFS.com.
Notify Me when it is readyRemote Selling of Acadia Pharmaceuticals Inc through IEX is under development on ETFS.com.
Notify Me when it is ready- Open
- Previous Close
- Bid
- Ask
- Day Range -
- 52 Week Range -
- Volume
- Avg. Volume
- Volume to USD
- Market Cap
- Beta
- PE Ratio
- Latest EPS
- EPS TTM
- Dividend
- Dividend Yield
- Ex-Dividend Date
- Revenue TTM
- Revenue per Share
- Revenue per Employee
- Profit Margin
- Gross Profit TTM
- Total Cash TTM
- Total Debt TTM
- Shares Outstanding
- Float
- Short Interest
- Short Ratio
- Insider Ownership
- Institution Ownership
ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) Given Average Rating of “Hold” by Brokerages via ETF Daily News
Zacks: Analysts Anticipate ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) to Post -$0.24 Earnings Per Share via ETF Daily News
-$0.24 EPS Expected for ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) This Quarter via ETF Daily News
$0.79 EPS Expected for Acadia Healthcare Company, Inc. (NASDAQ:ACHC) This Quarter via ETF Daily News
IDEAYA Biosciences (NASDAQ:IDYA) and ACADIA Pharmaceuticals (NASDAQ:ACAD) Head to Head Contrast via ETF Daily News
Lexicon Pharmaceuticals (NASDAQ:LXRX) Upgraded to “Buy” at Zacks Investment Research via ETF Daily News
CASI Pharmaceuticals Stock Set to Reverse Split on Wednesday, June 1st (NASDAQ:CASI) via ETF Daily News
Comparing Sierra Oncology (NASDAQ:SRRA) and Kiniksa Pharmaceuticals (NASDAQ:KNSA) via ETF Daily News
CASI Pharmaceuticals Stock Set to Reverse Split on Wednesday, June 1st (NASDAQ:CASI) via ETF Daily News
Zynerba Pharmaceuticals (NASDAQ:ZYNE) Rating Increased to Hold at StockNews.com via ETF Daily News
Acadia is trailblazing breakthroughs in neuroscience to elevate life. For more than 25 years it has been working at the forefront of healthcare to bring vital solutions to people who need them most. It developed and commercialized the first and only approved therapy for hallucinations and delusions associated with Parkinson's disease psychosis. Its late-stage development efforts are focused on dementia-related psychosis, negative symptoms of schizophrenia and Rett syndrome, and in early-stage clinical research it is exploring novel approaches to pain management, and cognition and neuropsychiatric symptoms in central nervous system disorders.
Analysis is available when the exchange & market are open.